This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 1992 Jun;35(6):724.

doi: 10.1002/art.1780350621.

Association of anti-topoisomerase I with cancer

N Rothfield, S Kurtzman, D Vazques-Abad, C Charron, L Daniels, B Greenberg

PMID: 1318051
DOI: 10.1002/art.1780350621

Comment

Association of anti-topoisomerase I with cancer

N Rothfield et al. Arthritis Rheum. 1992 Jun.

. 1992 Jun;35(6):724.

doi: 10.1002/art.1780350621.

Authors

N Rothfield, S Kurtzman, D Vazques-Abad, C Charron, L Daniels, B Greenberg

PMID: 1318051
DOI: 10.1002/art.1780350621

No abstract available

PubMed Disclaimer

Comment on

Clinical associations of anticentromere antibodies and antibodies to topoisomerase I. A study of 355 patients.
Weiner ES, Earnshaw WC, Senécal JL, Bordwell B, Johnson P, Rothfield NF. Weiner ES, et al. Arthritis Rheum. 1988 Mar;31(3):378-85. doi: 10.1002/art.1780310309. Arthritis Rheum. 1988. PMID: 2833902

Similar articles

A distinct syndrome including features of systemic sclerosis, erosive rheumatoid arthritis, anti-topoisomerase antibody, and rheumatoid factor.
Doran M, Wordsworth P, Bresnihan B, Fitzgerald O. Doran M, et al. J Rheumatol. 2001 Apr;28(4):921-2. J Rheumatol. 2001. PMID: 11327280 No abstract available.
Chromosome studies in systemic sclerosis with consideration of antibodies to topoisomerase I.
Tsay GJ, Lan JL, Li SY. Tsay GJ, et al. Ann Rheum Dis. 1992 May;51(5):624-6. doi: 10.1136/ard.51.5.624. Ann Rheum Dis. 1992. PMID: 1319697 Free PMC article.
The Predict Study: low risk for digital ulcer development in patients with systemic sclerosis with increasing disease duration and lack of topoisomerase-1 antibodies.
Hunzelmann N, Riemekasten G, Becker MO, Moinzadeh P, Kreuter A, Melchers I, Mueller-Ladner U, Meier F, Worm M, Lee H, Herrgott I, Pfeiffer C, Fierlbeck G, Henes J, Juche A, Zeidler G, Mensing H, Günther C, Sárdy M, Burkhardt H, Koehm M, Kuhr K, Krieg T, Sunderkötter C. Hunzelmann N, et al. Br J Dermatol. 2016 Jun;174(6):1384-7. doi: 10.1111/bjd.14367. Epub 2016 Mar 20. Br J Dermatol. 2016. PMID: 26708835 No abstract available.
Anti-topoisomerase-I and clinical findings in systemic sclerosis (scleroderma).
Shoenfeld Y, Grunebaum E, Laufer M, Zurgil N, Bakimer R, Lunderschmidt A, Valentini G, Tirri G, Blank M. Shoenfeld Y, et al. Isr J Med Sci. 1996 Jul;32(7):537-42. Isr J Med Sci. 1996. PMID: 8756980 Review.
[Anti-Scl-70 antibody (anti-topoisomerase I antibody)].
Kuwana M, Mimori T. Kuwana M, et al. Nihon Rinsho. 1999 Nov;57 Suppl:425-7. Nihon Rinsho. 1999. PMID: 10635873 Review. Japanese. No abstract available.

See all similar articles

Cited by

Risk factors for malignancy in systemic sclerosis patients.
Kaşifoğlu T, Yaşar Bilge Ş, Yıldız F, Özen G, Pehlivan Y, Yılmaz N, Tarhan F, Yılmaz S, Küçük A, Emmungil H, Koca SS, Çınar M, Direskeneli H, Erken E, Can G, Özmen M, Gönüllü E, Kisacik B, Aksu K, Karadağ O, Kasifoglu N, Arslantas D, Sahin F, Keser G, Yavuz S, Birlik M, Onat AM. Kaşifoğlu T, et al. Clin Rheumatol. 2016 Jun;35(6):1529-33. doi: 10.1007/s10067-016-3288-8. Epub 2016 Apr 27. Clin Rheumatol. 2016. PMID: 27118199
Autoantibodies in systemic sclerosis (scleroderma): clues for clinical evaluation, prognosis and pathogenesis.
Grassegger A, Pohla-Gubo G, Frauscher M, Hintner H. Grassegger A, et al. Wien Med Wochenschr. 2008;158(1-2):19-28. doi: 10.1007/s10354-007-0451-5. Wien Med Wochenschr. 2008. PMID: 18286246 Review.
Haematological Malignancies in Systemic Sclerosis Patients: Case Reports and Review of the World Literature.
Colaci M, Giuggioli D, Vacchi C, Ferri C. Colaci M, et al. Case Rep Rheumatol. 2017;2017:6230138. doi: 10.1155/2017/6230138. Epub 2017 May 4. Case Rep Rheumatol. 2017. PMID: 28546881 Free PMC article.
Autoantibody status in systemic sclerosis patients defines both cancer risk and survival with ANA negativity in cases with concomitant cancer having a worse survival.
Watad A, McGonagle D, Bragazzi NL, Tiosano S, Comaneshter D, Shoenfeld Y, Cohen AD, Amital H. Watad A, et al. Oncoimmunology. 2019 Mar 24;8(6):e1588084. doi: 10.1080/2162402X.2019.1588084. eCollection 2019. Oncoimmunology. 2019. PMID: 31069155 Free PMC article.
IgM, IgG, and IgA anti-DNA topoisomerase I antibodies in systemic sclerosis.
Martínez-Cordero E, Trejo AP, León DE. Martínez-Cordero E, et al. J Clin Lab Anal. 2009;23(6):408-16. doi: 10.1002/jcla.20342. J Clin Lab Anal. 2009. PMID: 19927342 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- Wiley